Go to main contents Go to main menus

사용자별 맞춤메뉴

자주찾는 메뉴

추가하기
닫기

Research Articles

contents area

detail content area

plasminogen activator inhibitor-1 as an early potential diagnostic marker for Alzheimer's disease
  • Date2018-02-05 17:37
  • Update2018-02-05 17:37
  • CountersignatureDivision of Research Planning
  • Tel043-719-8033
Experimental Gerontology, 2014, 01, 87─91

plasminogen activator inhibitor-1 as an early potential diagnostic marker for Alzheimer's disease

Jaeho Oh, Hye-Ja Lee, Ji-Hyun Song, Sang Ick Park, Hyunyoung Kim

Abstract

    Alzheimer's disease (AD) is the most common cause of dementia in individuals over 65 years old. However, to date, no useful early diagnostic markers for AD have been discovered. We examined the utility of plasminogen activator inhibitor-1 (PAI-1) as a potential biomarker for AD in subjects with mild cognitive impairment (MCI) or AD, as well as in nondemented healthy controls. Plasma PAI-1 levels were measured by enzyme-linked immunosorbent assays (ELISAs) in samples collected from 76 patients with MCI, 74 patients with AD, and 76 healthy controls. Our results show that plasma PAI-1 levels gradually increased as dementia progressed. The mean levels of plasma PAI-1 in patients with MCI and AD patients were significantly higher than those of in healthy controls. Consistently, neuropsychological examination (e.g., MMSE, CDR) also demonstrated significant correlations between the plasma PAI-1 levels and cognitive function. In conclusion, the level of plasma PAI-1 is a potential biomarker for the early detection and diagnosis of AD.


  • ISBN or ISSN: 0531-5565

  • 본 연구는 질병관리본부 연구개발과제(과제번호 2013-NG62001-00) 연구비를 지원받아 수행되었습니다.
  • This research was supported by a fund(code 2013-NG62001-00) by Research of Korea Centers for Disease Control and Prevention.


This public work may be used under the terms of the public interest source + commercial use prohibition + nonrepudiation conditions This public work may be used under the terms of the public interest source + commercial use prohibition + nonrepudiation conditions
TOP